medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 4

<< Back Next >>

Rev Mex Neuroci 2008; 9 (4)

Comparative study with random assignment and blind assessor to determine the effect on the soluble Vascular Cell Adhesion Molecules (sVCAM-1) of the Interferon Beta 1a biogeneric of Mexican production against an Interferon Beta 1a of international product

Barroso-Rodríguez NS, Núñez-Orozco L, Santos-Caballero N, de la Maza FM, Pérez-ZJA, Pérez-García JC, Nader-Kawachi J, Porras-Betancourt M, Uribe-Wiechers C, Revilla-Beltri J, Molina-Pérez A

Language: Spanish
References: 18
Page: 268-272
PDF size: 56.92 Kb.


ABSTRACT

Introduction: Due to the fact that the multiple sclerosis is an autoimmune disease characterized by the presence of multifocal areas of demyelinization in the nervous central system, the Interferon Beta 1a has been outlined as the viable treatment for this suffering, especially of the relapsing-remitting type. Objective: To compare two INF b 1a of different brands measuring their effect on the induction of them sVCAM-1. Material and methods: The effect of two different sources of Interferon Beta 1a (INF β 1a) on the soluble Vascular Cell Adhesion Molecules (sVCAM-1) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) was compared. Patients were randomized to receive either, INF β 1a (12 MUI, sc) from a standard international source, or INF β 1a from a Mexican source (same dose), three times weekly during 12 weeks. Serum sVCAM-1 levels were measured before and several weeks after treatment. Quality of life was also assesses before and three months after treatment. Results: sVCAM-1 levels were increased after treatment more than 60% in both groups. Adverse events were similar for both INF β 1a brands. Conclusion: Safety profiles and effect on serum sVCAM-1 were similar for both groups; no differences were found regarding gender, age, baseline or final disease status. This is the first worldwide study to compare the cellular immunologic effect of the international INF β 1a versus a biogeneric.


REFERENCES

  1. Compston A, Coles A. Multiple Sclerosis. Lancet 2002; 359: 1221- 31.

  2. Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by Interferon Beta and copolymer-1. J Autoimmun 2005; 24: 119-24.

  3. Rice G, Incorvaia B, Munari L, Ebers G, Polman C, D’Amico R, Filippini G. Interferon in relapsing –remitting multiple sclerosis. Cochrane Database 2001; Syst. Rev 4, CD0022002.

  4. Elovaara I, Ukkonen M, Leppäkynnäs M, Lehtimäki T, Luomala M, Peltola J, Dastidar P. Adhesion Molecules in Multiple Sclerosis: Relation to Subtypes of Disease and Methylprednisolone Therapy. Arch Neurol 2000; 57: 546-51.

  5. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with Interferon Beta-1b. Ann Neurol 1997; 41: 669-74.

  6. Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C, et al. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroinmunol 2005; 161: 169-76.

  7. Dhib-Jalbut S, Jiang H, Williams G. The effect of interferon-B 1b on lymphocyte-endothelial cell adhesion. J Neuroimmunol 1996; 71: 215-22.

  8. Correale J, Villa A. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 2007; 40: 148-60.

  9. Kraus J, Engelhardt B, Chatzimanolis N, Bauer R, Tofighi J, Kuehne BS, et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol 2002; 122: 175-85.

  10. Weber E, Springer T. Interaction of Very Late Antigen-4 with VCAMI supports transendothelial chemotaxis of monocytes by facilitating lateral migration. J Immunol 1998; 161: 6825-34.

  11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50 (1): 121-7.

  12. Chang CH, Cella D, Fernández O, Luque G, De Castro P, De Andrés C, et al. Quality of life in multiple sclerosis patients in Spain. Mult Scler 2002; 8: 527-31.

  13. Cella D, Dineen K, Arnason B, Reder A, Webster K, Karabatsos G. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47(1): 129-39.

  14. Sanz J, García-Vera MP. Análisis psicométrico de las versiones breves del “Inventario para la depresión, de Beck”. Psicología conductual 2007; 15(2): 125-32.

  15. Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000; 54: 2055-60.

  16. Schoenleber PJ, et al. Novel inhibitiors of sytodine induced Ik-ba phosphorylation and enfothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272: 21096- 103.

  17. Peterson J, Bo L, Mork S, Chang A, Ransohoff R, Trapp B. VCAM-1 positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropath Exp Neurol 2002; 61: 539-46.

  18. Carter R, Campbell I, O’Donnel K, Wicks I. Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin Exp Immunol 2002; 128: 44-51.




2020     |     www.medigraphic.com